ClinicalTrials.gg
CompletedNCT00528242Updated Nov 18, 2023

Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease

A Phase 2 interventional study of SLx-2101 and Placebo in Raynaud's Disease, sponsored by Response Pharmaceuticals. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Response Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To investigate the severity of secondary Raynaud's disease-related attacks during the 14 days 2101 dosing period.

Read the detailed description
  1. Number and cumulative duration of Raynaud's attacks.
  2. Adverse events and changes in vital signs.
  3. SLx-2101 pharmacokinetic parameters derived after dosing on Day 1 and Day maximum plasma concentration (Cmax), area under the plasma concentration-time curve (AUC0-4), time to Cmax (tmax), and accumulation ratio
02

Conditions studied

  • Raynaud's Disease

Browse trials for

03

In context

Raynaud Disease

81 studies on the registry are indexed under Raynaud Disease; 8 are open to participants now.

This study's enrollment of 17 is below the median of 30 across 67 interventional studies indexed under Raynaud Disease.

Browse Raynaud Disease studies →

Lead sponsor

Response Pharmaceuticals is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male and female ages 18 and 65 y.o.
  • Body weight within a body mass index range of 17 - 30 kg/m2 (inclusive).

Exclusion criteria

Exclusion Criteria:

  • to the active substance of SLx-2101or to any of the .
  • Past or present disease that is judged by the Investigator to have the potential to interfere with the study procedures, compromise safety, or affect the pharmacokinetic and pharmacodynamic evaluations
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    1

    SLx-2101

    Drug: SLx-2101

  • Placebo comparator
    2

    Matching Placebo Dose

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Raynaud's condition scores after 14 days of SLx-2101

    Time frame: 14 days

Secondary outcomes

  1. Safety and tolerability

    Time frame: 14 days

07

Study locations

1 site
  • University des Saarlandes
    Homburg, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2007
First posted
Sep 12, 2007
Start
Jun 2007
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Results delay requested
Dec 9, 2014
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00528242
Lead sponsor
Response Pharmaceuticals
Responsible party
Sponsor
First posted
Sep 12, 2007
Start date
Jun 2007
Primary completion
Mar 2008
Completion
Mar 2008
Last update
Nov 18, 2023

Study contacts

M Baumaker, MD
study director · University des Saarlandes

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SLX-2101

Start the discussion